Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Blood. 2012 Mar 29;119(13):3060-3. doi: 10.1182/blood-2011-10-383182. Epub 2012 Feb 8.
Mutations in the coding region of telomerase complex genes can result in accelerated telomere attrition and human disease. Manifestations of telomere disease include the bone marrow failure syndromes dyskeratosis congenita and aplastic anemia, acute myeloid leukemia, liver cirrhosis, and pulmonary fibrosis. Here, we describe a mutation in the CCAAT box (GCAAT) of the TERC gene promoter in a family in which multiple members had typical features of telomeropathy. The genetic alteration in this critical regulatory sequence resulted in reduced reporter gene activity and absent binding of transcription factor NF-Y, likely responsible for reduced TERC levels, decreased telomerase activity, and short telomeres. This is the first description of a pathogenic mutation in the highly conserved CCAAT box and the first instance of a mutation in the promoter region of TERC producing a telomeropathy. We propose that current mutation-screening strategies should include gene promoter regions for the diagnosis of telomere diseases. This clinical trial was registered at www.clinicaltrials.gov as #NCT00071045.
端粒酶复合物基因编码区的突变可导致端粒加速损耗和人类疾病。端粒疾病的表现包括骨髓衰竭综合征先天性角化不良和再生障碍性贫血、急性髓细胞性白血病、肝硬化和肺纤维化。在这里,我们描述了一个家族中端粒酶基因启动子 CCAAT 盒(GCAAT)的突变,该家族的多个成员具有典型的端粒病特征。该关键调节序列中的遗传改变导致报告基因活性降低,转录因子 NF-Y 结合缺失,可能导致 TERC 水平降低、端粒酶活性降低和端粒缩短。这是首次在高度保守的 CCAAT 盒中描述致病性突变,也是 TERC 启动子区域突变导致端粒病的首例。我们建议,目前的突变筛查策略应包括基因启动子区域,以诊断端粒疾病。该临床试验在 www.clinicaltrials.gov 上注册为 #NCT00071045。